Inventor · disambiguated record
Randy Ira Hecht
Also filed as: HECHT RANDY I · HECHT RANDY IRA
20 granted patents·8 pending applications·560 citations·filing 1982–2024
96Inventor score
Top patents by PatentIndex Score
28 records- 0198US8642546B2FGF21 mutant fusion polypeptides and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Feb 4, 2014·64 cites·11 claims
- 0298US8410051B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Apr 2, 2013·63 cites·21 claims
- 0398US8361963B2Uses of FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2011·Granted Jan 29, 2013·64 cites·4 claims
- 0498US8034770B2FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2009·Granted Oct 11, 2011·63 cites·15 claims
- 0597US8835385B2FGF21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Sep 16, 2014·48 cites·26 claims
- 0697US8795985B2FGF 21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Aug 5, 2014·48 cites·18 claims
- 0797US8618053B2FGF21 mutants multimers and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Dec 31, 2013·45 cites·18 claims
- 0897US8188040B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2010·Granted May 29, 2012·59 cites·21 claims
- 0994US9273106B2FGF mutants with reduced proteolysis and aggregationAMGEN INC·Filed 2013·Granted Mar 1, 2016·9 cites·21 claims
- 1094US7112659B2OB fusion protein compositions and methodsAMGEN INC·Filed 2005·Granted Sep 26, 2006·25 cites·9 claims
- 1194US6936439B2OB fusion protein compositions and methodsAMGEN INC·Filed 2003·Granted Aug 30, 2005·44 cites·5 claims
- 1293US11072640B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2018·Granted Jul 27, 2021·3 cites·12 claims
- 1393US10011642B2Methods of treating of diabetes and obesity using FGF21 mutantsAMGEN INC·Filed 2016·Granted Jul 3, 2018·4 cites·28 claims
- 1491US2025136653A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2024·Application pending·0 cites
- 1590US2024076333A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2023·Application pending·0 cites
- 1688US9493530B2FGF21 mutants comprising a mutation at position 98, 171 and/or 180AMGEN INC·Filed 2014·Granted Nov 15, 2016·10 cites·25 claims
- 1780US11840558B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2021·Granted Dec 12, 2023·0 cites·23 claims
- 1880US9279013B2FGF-21 mutants comprising polyethylene glycol and uses thereofWALKER KENNETH W·Filed 2009·Granted Mar 8, 2016·3 cites·53 claims
- 1979US2024010708A1Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methodsAMGEN INC·Filed 2023·Application pending·0 cites
- 2074US8080254B2OB fusion protein compositions and methodsMANN MICHAEL B·Filed 2006·Granted Dec 20, 2011·4 cites·4 claims
- 2171US2009082275A1Ob protein compositions and methodsAMGEN INC·Filed 2008·Application pending·0 cites
- 2263US10189890B2Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methodsAMGEN INC·Filed 2014·Granted Jan 29, 2019·0 cites·6 claims
- 2358US7524940B2OB protein compositions and methodsAMGEN INC·Filed 2002·Granted Apr 28, 2009·0 cites·9 claims
- 2457US2019085054A1Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methodsAMGEN INC·Filed 2018·Application pending·0 cites
- 2544US2016244497A1Fgf21 mutants and uses thereofAMGEN INC·Filed 2016·Application pending·0 cites
- 2644US2012052069A1Fgf21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2010·Application pending·0 cites
- 2735US4371462AMethod for purification of anterior pituitary hormonesGENEX CORP·Filed 1982·Granted Feb 1, 1983·4 cites·23 claims
- 2831US2002009798A1Ob protein compositions and methodsFiled 1999·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →